Drucker Wealth 3.0 LLC Sells 3,683 Shares of Sanofi $SNY

Drucker Wealth 3.0 LLC trimmed its holdings in Sanofi (NASDAQ:SNY) by 37.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,103 shares of the company’s stock after selling 3,683 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Sanofi were worth $298,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Ameritas Advisory Services LLC acquired a new stake in Sanofi in the second quarter worth about $28,000. Accent Capital Management LLC acquired a new stake in Sanofi in the first quarter worth about $29,000. Eastern Bank increased its position in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares during the period. Banque Transatlantique SA acquired a new stake in Sanofi in the first quarter worth about $33,000. Finally, Golden State Wealth Management LLC increased its position in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after purchasing an additional 545 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Sanofi stock opened at $48.09 on Friday. The firm has a market capitalization of $118.09 billion, a P/E ratio of 11.56, a PEG ratio of 1.17 and a beta of 0.51. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The business has a 50-day moving average of $48.27 and a 200-day moving average of $49.78. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the firm posted $1.73 earnings per share. Sanofi’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on SNY shares. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Barclays restated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.